Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 176 clinical trials
CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer

To evaluate the feasibility of administering HCQ, EVE or the combination in patients who have completed primary therapy for breast cancer and harbor bone marrow disseminated tumor cells.

tumor cells
primary tumor
triple-negative breast cancer
cancer
invasive breast cancer
  • 24 views
  • 25 Feb, 2022
  • 1 location
A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer

This is a phase III, double-blind, randomized, parallel-controlled, multicenter equivalence study to compare the efficacy and safety of pertuzumab biosimilar HLX11 vs. EU-Perjeta® on HER2-positive and HR-negative early-stage or locally advanced breast cancer with a primary tumor > 2 cm. Patients are random assignment to 2 arms and treatment with …

estrogen receptor
breast carcinoma
breast cancer staging
locally advanced breast cancer
carcinoma
  • 0 views
  • 09 May, 2022
A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer

This is a randomized, double-blinded, multicenter phase 3 clinical trial to evaluate the efficacy and safety of pyrotinib plus trastuzumab plus docetaxel versus placebo plus trastuzumab plus docetaxel in patients who have HER2 positive metastatic breast cancer and have not received systemic anticancer therapy for advanced disease.

metastasis
measurable disease
breast cancer
cancer treatment
trastuzumab
  • 0 views
  • 14 Feb, 2022
  • 1 location
Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients With Oligometastatic Breast Cancer

The prognosis for patients with metastatic breast cancer has improved continuously. Systemic therapies alone are not able to cure the disease permanently. Investigators initiated this randomized controlled multinational and multicenter clinical trial to analyse the impact of a local metastases-directed radiotherapy in addition to standard systemic therapy in patients with …

  • 0 views
  • 08 May, 2021
  • 14 locations
Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

This randomized phase III trial studies lymph node dissection and radiation therapy to see how well it works compared to radiation therapy alone in treating patients with breast cancer previously treated with chemotherapy and surgery. Lymph node dissection may remove cancer cells that have spread to nearby lymph nodes in …

estrogen receptor
sentinel node
her-2
erbb2
ductal carcinoma in situ
  • 496 views
  • 04 May, 2022
  • 6 locations
Adjuvant Palbociclib in Elderly Patients With Breast Cancer (Appalaches)

Phase II study to assess the efficacy of the combination of at least 5 year endocrine therapy and 2 year-palbociclib as adjuvant systemic treatment instead of adjuvant chemotherapy followed by endocrine therapy in older patients with stage II-III ER+/HER2- early breast cancer.

doxorubicin
estrogen receptor
cyclophosphamide
her-2
adjuvant chemotherapy
  • 4 views
  • 11 Apr, 2022
  • 76 locations
Pre Operative Trastuzumab in Operable Breast Cancer

Background Information and Rationale: Trastuzumab is a humanized monoclonal antibody that acts extracellularly on the erbB-2 receptor.Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the human epidermal growth factor receptor 2 (HER2/erbB-2),which has shown in both in vitro assays and in animals, to inhibit the proliferation of human tumour …

epidermal growth factor
her1
monoclonal antibodies
cancer
adjuvant chemotherapy
  • 71 views
  • 14 May, 2022
  • 1 location
Tusamitamab Ravtansine in Patients With CEACAM5-positive Advanced Solid Tumors (CARMEN-BT01)

Primary Objective: -To assess the antitumor activity of tusamitamab ravtansine in metastatic breast cancer (mBC) and metastatic pancreatic adenocarcinoma (mPAC) Secondary Objective: To assess the safety and tolerability of tusamitamab ravtansine To assess other efficacy parameters of tusamitamab ravtansine To assess the immunogenicity of tusamitamab ravtansine

  • 0 views
  • 15 Apr, 2022
  • 28 locations
Tusamitamab Ravtansine in Patients With CEACAM5-positive Advanced Solid Tumors (CARMEN-BT01)

Primary Objective: -To assess the antitumor activity of tusamitamab ravtansine in metastatic breast cancer (mBC) and metastatic pancreatic adenocarcinoma (mPAC) Secondary Objective: To assess the safety and tolerability of tusamitamab ravtansine To assess other efficacy parameters of tusamitamab ravtansine To assess the immunogenicity of tusamitamab ravtansine

  • 0 views
  • 29 Apr, 2022
  • 28 locations
Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection

This phase III trial studies how well axillary reverse mapping works in preventing lymphedema in patients with breast cancer undergoing axillary lymph node dissection. Axillary reverse mapping may help to preserve the lymph node drainage system around the breast so as to prevent lymphedema after surgery.

isosulfan blue
breast carcinoma
lcis
carcinoma
invasive breast cancer
  • 78 views
  • 11 Apr, 2022
  • 84 locations